Animab raised EUR 10M in a Series B round in 2025 to advance its animal health antibody platform.
Animab raised EUR 10M in a Series B in 2025. The company develops antibody-based treatments for animal health, applying monoclonal antibody technology to veterinary medicine. The Series B capital supports further pipeline development and potential commercialization efforts.